Stock fact sheet · data as of
Rein Therapeutics Inc. (RNTX): fair value, margin of safety and Wheel Score
Healthcare · Biotechnology · United States · Speculative / Distressed
Is RNTX undervalued?
Rein Therapeutics Inc. (RNTX) closed at 0.5860 on 16 Oct 2026. None of the nine GLS valuation models produced a positive value for the stock - the company lost money over the last twelve months, EPS -1.64, it pays no dividend and its debts exceed what its assets would fetch - so there is no GLS average fair value and no margin of safety to report. The quality, option and event numbers below still apply; the Quote page's Wall Street View shows what analysts expect instead.
The nightly engine files RNTX under Speculative / Distressed - negative earnings or a Piotroski score of 3 or less - which caps its Wheel Score at 45 and keeps it out of the Sunday Scan.
Nine valuation models for RNTX
Each model turns the latest filed numbers into a value per share; the GLS fair value is the simple average of the ones that produce a positive number. The last two rows are shown for reference and never enter the average. The Quote page lets you switch any model off and add your own margin of safety.
| Model | Value | vs price | What it measures |
|---|---|---|---|
| DCF | - | - | Present value of the projected free cash flows, discounted at the cost of capital; no value tonight |
| Graham Number | - | - | The most a defensive investor pays for the earnings and book value per share; no value tonight |
| Graham Growth | - | - | Graham's growth formula: EPS × (8.5 + 2 × growth), adjusted for bond yields; no value tonight |
| Lynch | - | - | EPS × the earnings growth rate (PEG of 1), growth capped at 25%; no value tonight |
| GLS Growth | - | - | EPS compounded ten years at the blended growth rate, discounted back at 15% a year; no value tonight |
| 10 Cap | - | - | Owner's earnings (operating cash flow less maintenance capex) capitalised at 10%; no value tonight |
| Payback Time | - | - | Eight years of compounded free cash flow: the price at which the business pays for itself; no value tonight |
| DDM | - | - | Dividend discount model: next year's dividend ÷ (10% − 3% growth); needs a dividend; no value tonight |
| EPV | - | - | Earnings power value: current EPS capitalised at 9% with no growth; no value tonight |
| Zombie (liquidation) | -0.1042 | -118% | Current assets less all liabilities, per share: the balance-sheet floor. Not in the average |
| Wall St target | 6.00 | +924% | Analysts' average 12-month price target. Not in the average |
Quality and financial health
Financial health is weak: RNTX passes 2 of the nine Piotroski tests. Our screens drop the stock at the health rule; a low score is often the reason a stock looks cheap on the valuation models. The GLS Moat score is low at 1.6 out of 10, which says the ten-year record of revenue, earnings, margins and returns on capital has been inconsistent - growth and shocks rather than steady compounding.
Returns on capital are thin or negative - ROIC -294.8%, ROE -294.8%, ROA -206.4% - with debt at 0.00 times equity and negative free cash flow.
Rein Therapeutics Inc. pays no dividend, so the DDM model does not apply and a covered-call holder earns only the premium and any price gain.
Institutional ownership scores 5/10, insider activity 10/10 and Congressional trading 5/10 on the GLS smart-money scales.
| Piotroski F-score | 2 / 9 | ROIC | -294.8% |
|---|---|---|---|
| GLS Moat | 1.6 / 10 | ROE | -294.8% |
| Debt / equity | 0.00 | ROA | -206.4% |
| Free-cash-flow yield | -115.0% | Payout ratio | 0% |
| Institutions | 5 / 10 | Insiders · Congress | 10 · 5 / 10 |
Wheel Score 31: No options
RNTX has no listed options in the nightly snapshot, so there is nothing to sell and the stock cannot be wheeled however good the business; the Wheel Score is capped at 39 and shown as "No options" (31 here). The valuation and quality numbers still apply to owning the shares outright.
Volume runs at 1.1M shares a day on a market cap of $16M, with a beta of 1.35 - a high beta, so the stock tends to move more than the market and a strike can be gapped through; the Stability part of the Wheel Score gives that 12 of 20.
| Part | Points | From | |
|---|---|---|---|
| Value | 13 / 25 | 0% margin of safety | |
| Health | 4 / 20 | Piotroski 2/9 | |
| Moat | 2 / 15 | moat 1.6/10 | |
| Premium | 0 / 20 | no option data | |
| Stability | 12 / 20 | 1.1M shares/day, $16M cap, beta 1.35 |
The Wheel Score ranks ~7,400 US stocks for selling cash-secured puts and covered calls; it is updated nightly and is not a recommendation. The walkthrough lesson shows how the score fits into a trade, start to finish.
Upcoming events
The next earnings report is due on 13 Nov 2026, 28 days away; a 30-45-day put sold today would expire after it, which is worth weighing against the premium.
Earnings, dividend, IPO, split and economic calendars for the whole market, filterable to your watchlists.
Similar stocks in Biotechnology
The 12 companies below are the closest to Rein Therapeutics Inc. by market cap within the Biotechnology industry, each with its own fact sheet; the Compare page puts up to eight of them side by side.
| Stock | Close | Fair value | MoS | Wheel | Mkt cap |
|---|---|---|---|---|---|
| DYAI Dyadic International, Inc. | 0.4194 | - | - | 35Weak | $17M |
| QNTM Quantum BioPharma Ltd. | 2.66 | 0.0860 | -2991% | 13No options | $17M |
| MRKR Marker Therapeutics, Inc. | 0.9200 | 1.08 | +15% | 30No options | $15M |
| EVAX Evaxion Biotech A/S | 2.80 | 31.73 | +91% | 39No options | $18M |
| JSPR Jasper Therapeutics, Inc. | 0.5321 | 1.16 | +54% | 36Weak | $18M |
| NEUP Neuphoria Therapeutics Inc. | 3.31 | 3,129.10 | +100% | 38No options | $18M |
| ATYR aTyr Pharma, Inc. | 0.1838 | - | - | 38Weak | $18M |
| BCDA BioCardia, Inc. | 0.9385 | 0.2082 | -351% | 13No options | $14M |
| LPCN Lipocine Inc. | 1.68 | 0.6721 | -150% | 15No options | $14M |
| KTTA Pasithea Therapeutics Corp. | 0.4101 | 7.85 | +95% | 37No options | $14M |
| COCP Cocrystal Pharma, Inc. | 1.03 | 0.4743 | -117% | 13No options | $20M |
| HIND Vyome Holdings, Inc. | 1.91 | 1.68 | -14% | 22No options | $13M |
Screen the whole market the same way
A free GLS Equity account gets you nightly fair value and the Wheel Score on ~7,400 US stocks, a watchlist, the scanner preview and the Sunday Scan - the same eight-rule screen, emailed every week. Pro adds the full put and call scanners, unlimited watchlists with alerts and the trade journal.
Start free See the Sunday ScanQuestions about RNTX
Is RNTX undervalued right now?
The GLS models could not value RNTX (the company lost money over the last twelve months, EPS -1.64, it pays no dividend and its debts exceed what its assets would fetch), so there is no fair value or margin of safety to compare the price of 0.5860 against.
What is the Wheel Score of RNTX and what does it mean?
RNTX has no listed options in our nightly snapshot, so it cannot be wheeled; its Wheel Score is capped at 39 and shown as "No options".
What is the GLS fair value for RNTX?
None of the nine GLS models produced a positive value for RNTX (the company lost money over the last twelve months, EPS -1.64, it pays no dividend and its debts exceed what its assets would fetch), so there is no GLS fair value tonight.
When does Rein Therapeutics Inc. report earnings next?
The next earnings report is due on 13 Nov 2026, 28 days from the data date of 16 Oct 2026. The Calendars page lists every upcoming report with its time of day.
Does RNTX have listed options, and how liquid are they?
No. The nightly options snapshot found no listed contracts on RNTX, so the wheel strategy cannot be run on it and the Wheel Score is capped at 39.